Literature DB >> 7656270

Host immune response in renal cell cancer: interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes.

M J Maeurer1, D M Martin, C Castelli, E Elder, G Leder, W J Storkus, M T Lotze.   

Abstract

Human renal cell cancer (RCC) is clearly responsive to immunotherapy. Clinical responses may be mediated by "non-specific" (e.g. natural killer, NK, cells) or "specific" MHC-class-I-restricted tumor-specific CD8+ T lymphocytes. Typically RCC progresses, however, despite significant infiltration of various lymphoid cells. We examined freshly isolated RCC tumor-infiltrating lymphocytes (TIL) derived from seven RCC patients for cytokine expression by the polymerase chain reaction (PCR). Established RCC tumor cell lines derived from these RCC patients were negative for interleukin-2 (IL-2), IL-4, IL-10, and interferon gamma and found to be positive for tumor necrosis factor alpha (TNF alpha), IL-6, IL-1 beta, granulocyte/macrophage-colony-stimulating factor (GM-CSF), and transforming growth factor beta 1 (TGF beta 1) message as detected by PCR. An identical pattern of cytokine mRNA expression was identified in other long-term RCC lines and in normal human kidney cells upon culture, but not in two Wilms tumor cell lines tested. Short-term-, and long-term-established RCC lines, but not Wilms tumor lines, secreted substantial levels of GM-CSF, TNF alpha, IL-1 beta, and IL-6 as detected by enzyme-linked immunosorbent assay. Both RCC lines and Wilms tumor lines secreted TGF beta 1. In comparison, normal kidney cells secreted IL-6 and GM-CSF, but not IL-1 beta, or TFG beta 1 under identical in vitro cell culture conditions. We applied PCR-based methods to characterize the cytokine mRNA expression pattern in immune cells infiltrating into renal cell cancer without the need for expansion of such effector cells in vitro. Examining freshly collected RCC TIL by PCR from patients with primary cell cell cancer, we could demonstrate that such cells, but not lympho-mononuclear cells harvested from normal human kidney tissue, typically exhibit IL-4 and IL-10 mRNA expression.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7656270     DOI: 10.1007/bf01527407

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  41 in total

1.  Production of colony-stimulating factor by tumor cells and the factor-mediated induction of suppressor cells.

Authors:  Y Tsuchiya; M Igarashi; R Suzuki; K Kumagai
Journal:  J Immunol       Date:  1988-07-15       Impact factor: 5.422

2.  Separation, phenotyping and limiting dilution analysis of T-lymphocytes infiltrating human solid tumors.

Authors:  T L Whiteside; S Miescher; J Hurlimann; L Moretta; V von Fliedner
Journal:  Int J Cancer       Date:  1986-06-15       Impact factor: 7.396

3.  Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones.

Authors:  P Salgame; J S Abrams; C Clayberger; H Goldstein; J Convit; R L Modlin; B R Bloom
Journal:  Science       Date:  1991-10-11       Impact factor: 47.728

4.  Immunophenotypic markers in renal cell carcinoma.

Authors:  B F Banner; J A Burnham; R R Bahnson; M S Ernstoff; H E Auerbach
Journal:  Mod Pathol       Date:  1990-03       Impact factor: 7.842

5.  CD4+ T cell clones isolated from human renal cell carcinoma possess the functional characteristics of Th2 helper cells.

Authors:  D D Schoof; Y Terashima; G E Peoples; P S Goedegebuure; J V Andrews; J P Richie; T J Eberlein
Journal:  Cell Immunol       Date:  1993-08       Impact factor: 4.868

6.  Interleukin 10 production correlates with pathology in human Leishmania donovani infections.

Authors:  H W Ghalib; M R Piuvezam; Y A Skeiky; M Siddig; F A Hashim; A M el-Hassan; D M Russo; S G Reed
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

7.  Tumor-specific lysis of human renal cell carcinomas by tumor-infiltrating lymphocytes: modulation of recognition through retroviral transduction of tumor cells with interleukin 2 complementary DNA and exogenous alpha interferon treatment.

Authors:  D J Schendel; B Gansbacher
Journal:  Cancer Res       Date:  1993-09-01       Impact factor: 12.701

8.  Specificity analysis of mouse monoclonal antibodies defining cell surface antigens of human renal cancer.

Authors:  C L Finstad; C Cordon-Cardo; N H Bander; W F Whitmore; M R Melamed; L J Old
Journal:  Proc Natl Acad Sci U S A       Date:  1985-05       Impact factor: 11.205

9.  Transforming growth factor-beta 1 is chemotactic for interleukin-2-activated natural killer cells.

Authors:  A A Maghazachi; A al-Aoukaty
Journal:  Nat Immun       Date:  1993 Mar-Apr

10.  Interleukin 2 expanded tumor-infiltrating lymphocytes in human renal cell cancer: isolation, characterization, and antitumor activity.

Authors:  A Belldegrun; L M Muul; S A Rosenberg
Journal:  Cancer Res       Date:  1988-01-01       Impact factor: 12.701

View more
  12 in total

Review 1.  Immunosuppression in human tumor-host interaction: role of cytokines and alterations in signal-transducing molecules.

Authors:  R Kiessling; K Kono; M Petersson; K Wasserman
Journal:  Springer Semin Immunopathol       Date:  1996

2.  IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer.

Authors:  J Riemensberger; A Böhle; S Brandau
Journal:  Clin Exp Immunol       Date:  2002-01       Impact factor: 4.330

Review 3.  Mesenchymal stem cells engineered for cancer therapy.

Authors:  Khalid Shah
Journal:  Adv Drug Deliv Rev       Date:  2011-06-29       Impact factor: 15.470

4.  Immune reconstitution after autologous hematopoietic transplantation with Lin-, CD34+, Thy-1lo selected or intact stem cell products.

Authors:  Rakesh K Singh; Michelle L Varney; Cheryl Leutzinger; Julie M Vose; Philip J Bierman; Suleyman Buyukberber; Kazuhiko Ino; Kevin Loh; Craig Nichols; David Inwards; Robert Rifkin; James E Talmadge
Journal:  Int Immunopharmacol       Date:  2007-04-20       Impact factor: 4.932

5.  Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy.

Authors:  Laura S Sasportas; Randa Kasmieh; Hiroaki Wakimoto; Shawn Hingtgen; Jeroen A J M van de Water; Gayatry Mohapatra; Jose Luiz Figueiredo; Robert L Martuza; Ralph Weissleder; Khalid Shah
Journal:  Proc Natl Acad Sci U S A       Date:  2009-03-05       Impact factor: 11.205

6.  Bimodal viral vectors and in vivo imaging reveal the fate of human neural stem cells in experimental glioma model.

Authors:  Khalid Shah; Shawn Hingtgen; Randa Kasmieh; Jose Luiz Figueiredo; Elisa Garcia-Garcia; Alberto Martinez-Serrano; Xandra Breakefield; Ralph Weissleder
Journal:  J Neurosci       Date:  2008-04-23       Impact factor: 6.167

7.  Interleukin 2 restores CD3-zeta chain expression but fails to generate tumour-specific lytic activity in tumour-infiltrating lymphocytes derived from human colorectal hepatic metastases.

Authors:  K F Yoong; D H Adams
Journal:  Br J Cancer       Date:  1998-04       Impact factor: 7.640

8.  Enhanced expression of IFN-gamma mRNA in CD4(+)or CD8(+)tumour-infiltrating lymphocytes compared to peripheral lymphocytes in patients with renal cell cancer.

Authors:  U Elsässer-Beile; M Rindsfüser; T Grussenmeyer; W Schultze-Seemann; U Wetterauer
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

9.  Renal cell carcinoma induces interleukin 10 and prostaglandin E2 production by monocytes.

Authors:  C Ménétrier-Caux; C Bain; M C Favrot; A Duc; J Y Blay
Journal:  Br J Cancer       Date:  1999-01       Impact factor: 7.640

10.  Disease-associated bias in T helper type 1 (Th1)/Th2 CD4(+) T cell responses against MAGE-6 in HLA-DRB10401(+) patients with renal cell carcinoma or melanoma.

Authors:  Tomohide Tatsumi; Lisa S Kierstead; Elena Ranieri; Loreto Gesualdo; Francesco P Schena; James H Finke; Ronald M Bukowski; Jan Mueller-Berghaus; John M Kirkwood; William W Kwok; Walter J Storkus
Journal:  J Exp Med       Date:  2002-09-02       Impact factor: 14.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.